Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy

American Journal of Physiology - Endocrinology and Metabolism

Volumn 310, Issue 9, 2016, Pages E744-E753

  Asmar, Ali ^a   Simonsen, Lene ^a   Asmar, Meena ^a   Madsbad, Sten ^b   Holst, Jens J ^c,d   Frandsen, Erik ^e   Moro, Cedric ^f   Sorensen, Charlotte M ^d   Jonassen, Thomas ^d   Bülow, Jens ^a,d  

^a BISPEBJERG HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f INSERM   (France)

Author keywords

Blood pressure; Cardiac output; Glomerular filtration rate; Glucagon like peptide 1; Heart rate; Renal plasma flow; Renal sodium excretion

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ION; METFORMIN; PLACEBO; SODIUM;

ADULT; ARTERIAL PRESSURE; ARTICLE; CENTRAL HEMODYNAMICS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEART RATE; HEMODYNAMICS; HORMONE RELEASE; HORMONE TRANSPORT; HUMAN; INFUSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY PLASMA FLOW; KIDNEY VEIN; MALE; MICTURITION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SODIUM INTAKE; STOMACH EMPTYING; SYSTOLIC BLOOD PRESSURE; URINE SAMPLING; VEIN CATHETERIZATION; BLOOD PRESSURE; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; METABOLISM; NATRIURESIS; URINE; VASCULARIZATION;

BLOOD PRESSURE; CARDIAC OUTPUT; DIABETES MELLITUS, TYPE 2; GLOMERULAR FILTRATION RATE; GLUCAGON-LIKE PEPTIDE 1; HEART RATE; HEMODYNAMICS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; MIDDLE AGED; NATRIURESIS; RENAL PLASMA FLOW; SODIUM;

EID: 84983749031     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00518.2015     Document Type: Article

References (47)

1. Asmar A, Simonsen L, Asmar M, Madsbad S, Holst JJ, Frandsen E, Moro C, Jonassen T, Bülow J. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am J Physiol Endocrinol Metab 308: E641–E649, 2015.
2. Bharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, Zinsmeister AR, Low PA. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 295: R874–R880, 2008.
3. Bie P, Wamberg S, Kjolby M. Volume natriuresis vs. pressure natriuresis. Acta Physiol Scand 181: 495–503, 2004.
4. Bogert LW, van Lieshout JJ. Non-invasive pulsatile arterial pressure and stroke volume changes from the human finger. Exp Physiol 90: 437–446, 2005.
5. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 55: 845–855, 1975.
6. Finta KM, Rocchini AP, Moorehead C, Key J, Katch V. Urine sodium excretion in response to an oral glucose tolerance test in obese and nonobese adolescents. Pediatrics 90: 442–446, 1992.
7. Gustavson SM, Chen D, Somayaji V, Hudson K, Baltrukonis DJ, Singh J, Boyden TL, Calle RA. Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. Diab Obes Metab 13: 1056–1058, 2011.
8. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89: 3055–3061, 2004.
9. Halbirk M, Norrelund H, Moller N, Holst JJ, Schmitz O, Nielsen R, Nielsen-Kudsk JE, Nielsen SS, Nielsen TT, Eiskjaer H, Botker HE, Wiggers H. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 298: H1096–H1102, 2010.
10. Hlebowicz J, Lindstedt S, Björgell O, Dencker M. The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure. Cardiovasc Ultrasound 9: 43, 2011.
11. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409–1439, 2007.
12. Hopkins ND, Cuthbertson DJ, Kemp GJ, Pugh C, Green DJ, Cable NT, Jones H. Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients. Diabetes Obes Metab 15: 770–773, 2013.
13. Horita S, Seki G, Yamada H, Suzuki M, Koike K, Fujita T. Insulin resistance, obesity, hypertension, and renal sodium transport. Int J Hypertens 2011: 391762, 2011.
14. Imholz BP, Wieling W, van Montfrans GA, Wesseling KH. Fifteen years experience with finger arterial pressure monitoring: assessment of the technology. Cardiovasc Res 38: 605–616, 1998.
15. Jensen EP, Poulsen SS, Kissow H, Holstein-Rathlou NH, Deacon CF, Jensen BL, Holst JJ, Sorensen CM. Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. Am J Physiol Renal Physiol 308: F867–F877, 2015.
16. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol 11: 64, 2012.
17. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19: 567–575, 2013.
18. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48: 736–743, 2007.
19. Langewouters GJ, Goedhard WJ, Wesseling KH. [The effect of aging and sclerosis on the viscoelastic properties of the human thoracic aorta]. Tijdschr Gerontol Geriatr 16: 61–70, 1985.
20. Langewouters GJ, Wesseling KH, Goedhard WJ. The static elastic properties of 45 human thoracic and 20 abdominal aortas in vitro and the parameters of a new model. J Biomech 17: 425–435, 1984.
21. Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 38: 132–139, 2015.
22. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulindependent) diabetes mellitus. Diabetologia 35: 771–776, 1992.
23. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53: 654–662, 2004.
24. Mendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol 74: 437–444, 2012.
25. Nandy D, Johnson C, Basu R, Joyner M, Brett J, Svendsen CB, Basu A. The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diab Vasc Dis Res 11: 419–430, 2014.
26. Nathanson D, Ullman B, Löfström U, Hedman A, Frick M, Sjöholm A, Nyström T. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 55: 926–935, 2012.
27. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209–E1215, 2004.
28. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535–539, 1994.
29. Oyama J, Higashi Y, Node K. Do incretins improve endothelial function? Cardiovasc Diabetol 13: 21, 2014.
30. Paolisso G, Manzella D, Tagliamonte MR, Rizzo MR, Gambardella A, Varricchio M. Effects of different insulin infusion rates on heart rate variability in lean and obese subjects. Metabolism 48: 755–762, 1999.
31. Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB, Meisner S, Hovendal C, Knop FK, Vilsboll T, Holst JJ. Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. Eur J Endocrinol 169: 187–201, 2013.
32. Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, Hvelplund A, Bardram L, Calatayud D, Knudsen LB. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155: 1280–1290, 2014.
33. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 30: 219–225, 1981.
34. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 96: 4104–4113, 1997.
35. Shields RW Jr. Heart rate variability with deep breathing as a clinical test of cardiovagal function. Cleve Clin J 76, Suppl 2: S37–S40, 2009.
36. Sivertsen J, Rosenmeier J, Holst JJ, Vilsboll T. The effect of glucagonlike peptide 1 on cardiovascular risk. Nat Rev Cardiol 9: 209–222, 2012.
37. Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord 15: 197–207, 2014.
38. Skov J, Dejgaard A, Frokiaer J, Holst JJ, Jonassen T, Rittig S, Christiansen JS. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 98: E664–E671, 2013.
39. Soveri I, Berg UB, Björk J, Elinder CG, Grubb A, Mejare I, Sterner G, Bäck SE; SBU GFR Review Group. Measuring GFR: a systematic review. Am J Kidney Dis 64: 411–424, 2014.
40. Stok WJ, Baisch F, Hillebrecht A, Schulz H, Meyer M, Karemaker JM. Noninvasive cardiac output measurement by arterial pulse analysis compared with inert gas rebreathing. J Appl Physiol 74: 2687–2693, 1993.
41. Tack CJ, Lenders JW, Willemsen JJ, van Druten JA, Thien T, Lutterman JA, Smits P. Insulin stimulates epinephrine release under euglycemic conditions in humans. Metabolism 47: 243–249, 1998.
42. Thomsen K. Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron 37: 217–223, 1984.
43. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22: 1137–1143, 1999.
44. Torekov SS, Kipnes MS, Harley RE, Holst JJ, Ehlers MR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes Obes Metab 13: 639–643, 2011.
45. Vollenweider L, Tappy L, Owlya R, Jequier E, Nicod P, Scherrer U. Insulin-induced sympathetic activation and vasodilation in skeletal muscle. Effects of insulin resistance in lean subjects. Diabetes 44: 641–645, 1995.
46. Vollenweider P, Randin D, Tappy L, Jequier E, Nicod P, Scherrer U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest 93: 2365–2371, 1994.
47. Vollenweider P, Tappy L, Randin D, Schneiter P, Jequier E, Nicod P, Scherrer U. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest 92: 147–154, 1993.